AIM
CLRB icon

Acrospire Investment Management’s Cellectar Biosciences CLRB Stock Holding History

Acrospire Investment Management’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-3
Closed -$10K – 2238
2016
Q4 		$10K Buy
3
+2
+200% +$10.8K ﹤0.01% 1943
2016
Q3 		$10K Buy
+1
New +$8.2K 0.01% 1691

Other funds holding CLRB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
WAM
Wealthspire Advisors (Maryland) Potomac, Maryland $2.84B AUM 10.91% 1-Year Est. Return

Acrospire Investment Management's CLRB Position: Q1 2017 in Review

Acrospire Investment Management sold out of Cellectar Biosciences (CLRB) in Q1 2017, closing a stake of 3 shares — an estimated $10K sold.

Acrospire Investment Management first reported a position in CLRB in Q3 2016 and held it in 2 quarters. The position peaked at $10K in Q4 2016. 9 funds tracked by Wall St. Rank hold CLRB as of Q1 2017.

  • Acrospire Investment Management reported no remaining Cellectar Biosciences position as of Q1 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 3 Cellectar Biosciences shares in Q1 2017, an estimated $10K.
  • Acrospire Investment Management first reported a position in Cellectar Biosciences in Q3 2016 and held it in 2 quarters.
  • Acrospire Investment Management's Cellectar Biosciences position peaked at $10K in Q4 2016.
  • 9 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q1 2017.

Based on Acrospire Investment Management's 13F filing for Q1 2017, filed 4 May 2017.